Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020) | Latest Study

Market Research Reports

Researchmoz added Most up-to-date research on “Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020)” to its huge collection of research reports.

The report titled Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020), provides and in-depth analysis of the global CINV market and respective drugs. The report gives an insight of the global CINV market by 5-HT3 and NK-1 drug receptor antagonists.

The report also includes the analysis of North American CINV market. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global CINV market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

To Get Sample Copy of Report visit @

The competition in global CINV market is fragmented as the specific treatment for CINV is still at a nascent stage with several drugs by multiple competitors already thriving the market and some are under formulation.

The key players of the global CINV market, Heron Therapeutics, Inc., Merck & Co., Inc., Novartis AG and TESARO, Inc. are also profiled with their financial information and respective business strategies

Country Coverage

North America

Company Coverage

Heron Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG

Browse Our Latest Press Releases @

Executive Summary

Chemotherapy induced nausea and vomiting (CINV) is the most dreaded side-effect of chemotherapy among the cancer patients. Therefore, sometimes patients either do not undergo the chemotherapy or discontinue in the prior year of treatment. CINV is also of various types such as acute, breakthrough, delayed, anticipatory and refractory. HEC and MEC regimens cause the CINV. Several treatments of CINV are on the verge of emergence such as 5-HT3 receptor antagonist, NK-1 blocker, corticosteroids, cannabinoids and dopamine antagonists. However, there are several unmet medical needs in the field of HEC regimen of delayed CINV.

Global CINV market has increased at a significant CAGR during the years 2013-2015 and projections are made that the market would rise tremendously in the next four years i.e. 2016-2020. The CINV market is expected to increase due to growth in global cancer incidence, increasing health expenditure and the increasing outbreak of factors working towards causing cancer. Yet, the market faces some challenges such as discontinuation of chemotherapy treatment, several unmet medical needs, no drugs for the HEC regimen in the delayed CINV, etc.

Make an Enquiry of this report @